Dermatologic Adverse Events With Immune Checkpoint Inhibitors in Metastatic Melanoma
Source: Oncology Nurse Advisor, August 2021
Researchers identified a possible association between female sex and dermatologic adverse events (AEs) during treatment of melanoma using immune checkpoint inhibitor therapy. Findings were presented in a report in the Journal of the American Academy of Dermatology.1
